573 related articles for article (PubMed ID: 17954615)
1. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of anakinra in subjects with different levels of renal function.
Yang BB; Baughman S; Sullivan JT
Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
[TBL] [Abstract][Full Text] [Related]
3. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of repaglinide in subjects with renal impairment.
Marbury TC; Ruckle JL; Hatorp V; Andersen MP; Nielsen KK; Huang WC; Strange P
Clin Pharmacol Ther; 2000 Jan; 67(1):7-15. PubMed ID: 10668848
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
Brier ME; Gaylor SK; McGovren JP; Glue P; Fang A; Aronoff GR
J Clin Pharmacol; 2011 May; 51(5):731-8. PubMed ID: 20484616
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.
Teichert J; Tuemmers T; Achenbach H; Preiss C; Hermann R; Ruus P; Preiss R
J Clin Pharmacol; 2005 Mar; 45(3):313-28. PubMed ID: 15703366
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment.
Türck D; Weber W; Sigmund R; Budde K; Neumayer HH; Fritsche L; Rominger KL; Feifel U; Slowinski T
J Clin Pharmacol; 2004 Feb; 44(2):163-72. PubMed ID: 14747425
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.
Courtney R; Sansone A; Smith W; Marbury T; Statkevich P; Martinho M; Laughlin M; Swan S
J Clin Pharmacol; 2005 Feb; 45(2):185-92. PubMed ID: 15647411
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
Zhou XJ; Swan S; Smith WB; Marbury TC; Dubuc-Patrick G; Chao GC; Brown NA
Antimicrob Agents Chemother; 2007 Dec; 51(12):4231-5. PubMed ID: 17875994
[TBL] [Abstract][Full Text] [Related]
13. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin.
Lefèvre G; Duval M; Gauron S; Brookman LJ; Rolan PE; Morris TM; Piraino AJ; Morgan JM; Palmisano M; Close P
Clin Pharmacol Ther; 1997 Jul; 62(1):50-9. PubMed ID: 9246019
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of nicotine in kidney failure.
Molander L; Hansson A; Lunell E; Alainentalo L; Hoffmann M; Larsson R
Clin Pharmacol Ther; 2000 Sep; 68(3):250-60. PubMed ID: 11014406
[TBL] [Abstract][Full Text] [Related]
16. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.
Gillotin C; Bagnis C; Mamet JP; Peck RW; Deray G
Int J Clin Pharmacol Ther; 1997 Nov; 35(11):522-6. PubMed ID: 9401835
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment.
Flor S; Guay D; Opsahl J; Tack K; Matzke G
Int J Clin Pharmacol Res; 1991; 11(3):115-21. PubMed ID: 1809697
[TBL] [Abstract][Full Text] [Related]
18. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment.
Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL
Epilepsy Res; 2014 Jul; 108(5):891-901. PubMed ID: 24725807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
